27.61
+0.93(+3.49%)
Currency In CNY
Sector
Healthcare
Industry
Biotechnology
Employees
470
First IPO Date
June 08, 2021
| Name | Title | Pay | Year Born |
| Mr. Shaowen Fan | Chairman of the Board & GM | 0 | 1953 |
| Mr. Hengjun Ma | Executive Vice General Manager | 0 | 1974 |
| Mr. Wei Wu | Secretary of the Board of Directors | 0 | 1982 |
| Mr. Yong Tan | Finance Director | 0 | 1974 |
Olymvax Biopharmaceuticals Inc. develops and supplies vaccines. The company offers vaccines for Tetanus, a deadly infectious disease that causes nervous system toxicity by toxigenic clostridium tetanus; and haemophilus influenzae type b. it also develops vaccines for Staphylococcus aureus, a pathogenic bacterium that causes hospital infection and community infection; and Group A streptococcus disease. The company was founded in 2009 and is based in Chengdu, China.